Boost cancer prevention and survival through Asian nutritional diet

September 6, 2022 Providence Cancer Institute of Oregon

Share this Article
Facebook
Twitter
LinkedIn

Providence registered dietitian Grace Laman, MS, RDN, CSO, explains how to decide the best diet before, during and after cancer treatment. She also shares the most current research on cancer prevention and diet and helps you understand the right supplements to use.

This educational talk is presented by Providence Cancer Institute and the Asian Health and Service Center.

About the presenter

Grace Laman, MS, RDN, CSO, is a clinical dietitian at Providence. She provides nutrition guidance and counseling to help support the needs of patients before, during and after cancer treatment. Grace has spent her career counseling patients with a variety of clinical conditions, most recently focusing on supporting the nutrition needs of cancer patients.

Learn more about nutrition counseling at Providence.

Saint John’s among first worldwide to implant innovative device in heart patient to reduce blood clot, stroke risk

Dr. Shephal Doshi co-leads international clinical trial to evaluate Conformal Medical’s novel CLAAS implant

5 ways Providence is investing in Oregon’s health

When we talk about how Providence helps others, you might think first of health care for patients. But ther...

Most Recent Articles

Growing hope

Boost cancer prevention and survival through Asian nutritional diet

About the presenter

Previous Article

Next Article

Most Recent Articles

When a stroke robbed Lauren of her balance, the team on 4K – Providence Acute Rehabilitation Center – helped her regain what she lost with a little help from sunflowers, marigolds and little bugs.

The bariatric programs at Providence Little Company of Mary’s San Pedro and Torrance locations offer effective, long-term weight-loss solutions.

Providence South Division Cancer Institute earns national recognition as a top cancer program

Hospital program the only one recognized in Greater L.A. Area

More than 2,000 years ago, Hippocrates—the father of modern medicine—suggested that all diseases begin in the gut. With mounting evidence showing a connection between gut health and everything from au

Grounding allows us to use the earth’s negative electric charge to stabilize and rebalance our body’s accumulated positive charges. Contact with the vast supply of electrons on the earth’s surface—thi

Despite the sometimes dramatic improvements that have been made in other cancers, lung cancer survival has only slightly improved over the past several decades. Fortunately, that’s beginning to change

Rob Sears had been troubled by an increasingly erratic heartbeat for years. He finally found help from Dr. Shephal Doshi and a leading-edge minimally invasive procedure.

A special request for our patients and visitors – Farsi and Spanish translation further below:

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The team at the Adult and Pediatric Cochlear Implant Program, Dr. Courtney Voelker and Dr. Rebecca Lewis, restored Father Timothy McGowan’s hearing so he could get back to the work he loves.

Kadlec offering Prevention4ME for detection of breast and other cancers.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

In 2023, Providence Alaska contributed $265,000 to Catholic Social Services’ Medical Respite program, which provides recuperative living quarters for patients experiencing homelessness.

Learn why a proposed FSED is not right for our community.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.